Home > Name List By t > Trifluridine Canada

CAS No 70-00-8 , Trifluridine Search by region : Canada

  • Name: Trifluridine
  • Synonyms: Trifluorothymidine; alpha,alpha,alpha-Trifluorothymidine; trifluridine; 5-(Trifluoromethyl)-2-deoxyuridine;2'-Deoxy-5-(trifluoromethyl)uridine; Trifluorothymine deoxyriboside;2-Deoxy-5-(trifluoromethyl)uridine; 5-(Trifluoromethyl)-2'-deoxyuridine;Trifluridine;
  • CAS Registry Number:
  • Melting Point: 190-193 ºC
  • Density: 1.646g/cm3
  • Refractive index: 1.534
  • Safety Statements: R20/21/22;R40
  • Hazard Symbols: Xi: Irritant;
  • EINECS: 200-722-8
  • Molecular Weight: 296.20
  • InChI: InChI=1/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
  • Risk Statements: S22;S36
  • Molecular Formula: C10H11F3N2O5
  • Molecular Structure:CAS No:70-00-8 Trifluridine

Related products

Select to

70-00-8 2'-Deoxy-5-(trifluoromethyl)-uridine

  • 2'-Deoxy-5-(trifluoromethyl)-uridine
  • Canada General Intermediates of Canada, Inc. [Manufacturer]
  • Tel: 780-483-2783
  • Fax: 780-483-2971
  • Address: General Intermediates of Canada, Inc.
    17303 - 108 Avenue
    Edmonton, Alberta
    CANADA T5S 1G2 null,nullCanada
Contact Supplier

Select to

References of Trifluridine
Title: Trifluridine
CAS Registry Number: 70-00-8
CAS Name: a,a,a-Trifluorothymidine
Synonyms: 2¢-deoxy-5-(trifluoromethyl)uridine; 5-(trifluoromethyl)-2¢-deoxyuridine; F3TDR
Manufacturers' Codes: NSC-75520
Trademarks: TFT Thilo (Alcon-Thilo); Virophta (Dulcis); Viroptic (Burroughs Wellcome)
Molecular Formula: C10H11F3N2O5
Molecular Weight: 296.20
Percent Composition: C 40.55%, H 3.74%, F 19.24%, N 9.46%, O 27.01%
Literature References: Prepn: C. Heidelberger et al., J. Am. Chem. Soc. 84, 3597 (1962); eidem, J. Med. Chem. 7, 1 (1964); C. Heidelberger, US 3201387 (1965 to U.S. Dept. HEW). Crystal structure: A. H. Tench, Diss. Abstr. Int. B 33, 3587 (1973). NMR study: R. J. Cushley et al., J. Am. Chem. Soc. 90, 709 (1968). Metabolism: D. L. Dexter et al., Cancer Res. 32, 247 (1972); W. J. O'Brien, H. F. Edelhauser, Invest. Ophthalmol. Visual Sci. 16, 1093 (1977). Pharmacodynamics: B. L. Wigdahl, J. R. Parkhurst, Antimicrob. Agents Chemother. 14, 470 (1978); G. J. Smith et al., Biochem. Biophys. Res. Commun. 83, 1538 (1978). Teratogenicity study: M. Itoi et al., Arch. Ophthalmol. 93, 46 (1975). Cytotoxicity and mutagenicity study: E. Huberman, C. Heidelberger, Mutat. Res. 14, 130 (1972). Clinical studies: H. E. Kaufman, Invest. Ophthalmol. Visual Sci. 17, 941 (1978); R. A. Hyndiuk et al., Arch. Ophthalmol. 96, 1839 (1978). Review of mechanism of antiviral activity: C. Heidelberger, Ann. N.Y. Acad. Sci. 255, 317 (1975). Review of pharmacology and therapeutic use: A. A. Carmine et al., Drugs 23, 329-353 (1982).
Properties: Cryst from ethyl acetate, mp 186-189°. uv max (0.1N HCl): 260 nm (e 9960); (0.1N NaOH): 260 nm (e 6590).
Melting point: mp 186-189°
Absorption maximum: uv max (0.1N HCl): 260 nm (e 9960); (0.1N NaOH): 260 nm (e 6590)
Therap-Cat: Antiviral (ophthalmic).
Keywords: Antiviral; Purines/Pyrimidinones.